We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+5.38%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.43B
AUM Growth
+$209M
Cap. Flow
+$182M
Cap. Flow %
12.72%
Top 10 Hldgs %
28.58%
Holding
96
New
13
Increased
36
Reduced
31
Closed
4

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$34M
2
COR icon
Cencora
COR
+$18.2M
3
TDOC icon
Teladoc Health
TDOC
+$17.4M
4
ISRG icon
Intuitive Surgical
ISRG
+$16.6M
5
MCK icon
McKesson
MCK
+$16.1M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$27M
2
ABBV icon
AbbVie
ABBV
+$14.1M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$12.4M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.74M
5
GKOS icon
Glaukos
GKOS
+$7.91M

Sector Composition

Rank Sector Weight
1 Healthcare 96.33%
2 Industrials 0.98%
3 Technology 0.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IOVA icon
51
Iovance Biotherapeutics
IOVA
$2.9B
$9.34M 0.65%
295,000
-25,000
-8% -$1.04M
EW icon
52
Edwards Lifesciences
EW
$53B
$9.2M 0.64%
110,000
-15,000
-12% -$1.27M
ACCD
53
DELISTED
Accolade Inc
ACCD
$9.07M 0.63%
200,000
+50,000
+33% +$2.41M
RDUS
54
DELISTED
Radius Health, Inc.
RDUS
$8.97M 0.63%
430,000
-51,826
-11% -$1.09M
GTHX
55
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$7.82M 0.55%
325,000
+85,000
+35% +$1.98M
ONEM
56
DELISTED
1Life Healthcare
ONEM
$7.82M 0.55%
+200,000
New +$9.39M
DVAX
57
DELISTED
Dynavax Technologies
DVAX
$7.73M 0.54%
786,211
-139,323
-15% -$1.15M
EPIX
58
DELISTED
ESSA Pharma
EPIX
$7.55M 0.53%
260,000
+103,300
+66% +$2.4M
SILK
59
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$7.39M 0.52%
146,000
+21,000
+17% +$1.17M
KYNB
60
Kyntra Bio
KYNB
$28.2M
$6.94M 0.48%
8,000
+2,200
+38% +$2.34M
PHAT icon
61
Phathom Pharmaceuticals
PHAT
$693M
$6.57M 0.46%
175,000
– –
SWAV
62
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$6.51M 0.45%
50,000
-10,000
-17% -$1.2M
MGTX icon
63
MeiraGTx Holdings
MGTX
$1.21B
$6.49M 0.45%
450,000
– –
ADVM
64
DELISTED
Adverum Biotechnologies
ADVM
$6.41M 0.45%
65,000
+2,500
+4% +$300K
OSH
65
DELISTED
Oak Street Health, Inc.
OSH
$6.24M 0.44%
115,000
+55,000
+92% +$3.06M
INOV
66
DELISTED
Inovalon Holdings, Inc. Class A Common Stock
INOV
$6.19M 0.43%
+215,000
New +$5.53M
RVNC
67
DELISTED
Revance Therapeutics, Inc.
RVNC
$6.15M 0.43%
220,000
– –
ALXN
68
DELISTED
Alexion Pharmaceuticals
ALXN
$6.12M 0.43%
40,000
-80,000
-67% -$12.4M
ZLAB icon
69
Zai Lab
ZLAB
$2.65B
$6M 0.42%
+45,000
New +$6.97M
RPRX icon
70
Royalty Pharma
RPRX
$25.8B
$5.67M 0.4%
130,000
-120,000
-48% -$5.69M
BIIB icon
71
Biogen
BIIB
$30.6B
$5.46M 0.38%
19,500
-20,500
-51% -$5.53M
HCAT icon
72
Health Catalyst
HCAT
$129M
$5.38M 0.38%
+115,000
New +$5.57M
RIGL icon
73
Rigel Pharmaceuticals
RIGL
$778M
$5.2M 0.36%
152,000
-21,618
-12% -$856K
ANNX icon
74
Annexon
ANNX
$883M
$5.01M 0.35%
180,000
+50,000
+38% +$1.38M
RCM
75
DELISTED
R1 RCM Inc. Common Stock
RCM
$4.94M 0.34%
+200,000
New +$5.28M
1 2
3
4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2021 Portfolio in Review

As of Q1 2021, Rhenman & Partners Asset Management held 96 positions worth $1.43B, up 17% from $1.23B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management deployed $182M of net new capital in Q1 2021, opening 13 new positions and adding to 36 existing holdings. Its largest new stake was Cencora: 167,957 shares worth $19.8M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 98% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $27M trimmed.

  • Rhenman & Partners Asset Management's largest Q1 2021 buy was Cencora: 167,957 shares worth $19.8M.
  • Rhenman & Partners Asset Management added most to Johnson & Johnson in Q1 2021, an estimated $34M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2021 reduction was BioMarin Pharmaceuticals, cutting an estimated $27M.
  • Rhenman & Partners Asset Management fully exited Agios Pharmaceuticals in Q1 2021, selling an estimated $5.63M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $1.43B portfolio in Q1 2021.
  • Rhenman & Partners Asset Management opened 13 new positions and closed 4 in Q1 2021.
  • Rhenman & Partners Asset Management's portfolio value rose 17% quarter-over-quarter to $1.43B.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2021, filed 14 May 2021.